Table 1.
Treat group | Pretargeting comp. (20 μg/mL, 130/180 nM) | Drug delivery comp. (50 μg/mL, 600 nM) |
---|---|---|
1 | 5D3(TCO)8 | ALB(DM1)3.3(PEG4-Tz)10 |
2 | F(ab′)2(TCO)8 | ALB(DM1)3.3(PEG4-Tz)10 |
3 | 5D3 | ALB(DM1)3.3(PEG4-Tz)10 |
4 | F(ab′)2 | ALB(DM1)3.3(PEG4-Tz)10 |
5 | 5D3(TCO)8 | |
6 | F(ab′)2(TCO)8 | |
7 | 5D3 | |
8 | F(ab′)2 | |
9 | DM1 (2 μM)a | |
10 | ALB(DM1)3.3(PEG4-Tz)10 |
The concentration of pure DM1 was equivalent for DM1 content in a drug delivery component.